NCT07050147

Brief Summary

The aim of the study is to investigate the influence of respiratory support on diaphragmatic function (O2, NHF, NIV). The effects on the diaphragm, the respiratory values (FEV1, respiratory rate) and the subjective well-being of the patients during the therapy phases will be measured. The primary objective of the clinical study is to investigate the differences in respiratory support with regard to the change in diaphragmatic kinetics and morphology (Tdi; TEx; Tdi, ee, Tdi, pi, ΔTdi, TFdi) as a function of respiratory rate. For both ventilation modes, the influence on the respiratory situation, the respiratory muscle pump and adverse events will also be analysed. This is done using defined variables (FEV1, FEV1%VC, respiratory rate, frequency and type of adverse events (AEs), subjective satisfaction with the test product (Borg scale)).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
35

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2019

Completed
5.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2025

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

January 3, 2025

Completed
6 months until next milestone

First Posted

Study publicly available on registry

July 3, 2025

Completed
Last Updated

July 3, 2025

Status Verified

June 1, 2025

Enrollment Period

5.5 years

First QC Date

January 3, 2025

Last Update Submit

June 24, 2025

Conditions

Keywords

nasal high flowNIVdiaphragmsonography

Outcome Measures

Primary Outcomes (1)

  • Sonographic measurements of diaphragm thickness

    Tdi ee in mm = Diaphragm thickness is determined by measuring the distance between the diaphragmatic pleura and the diaphragm/peritoneum border at maximum expiration

    after 30 minutes use

Secondary Outcomes (6)

  • DEx

    30 minutes

  • FEV1

    30 min

  • Tiffeneau - index

    30 min

  • Respiratory rate

    30 min

  • Tdi pi

    30 minutes

  • +1 more secondary outcomes

Study Arms (2)

Nasal high flow

ACTIVE COMPARATOR
Device: Nasal high flow

NIV

ACTIVE COMPARATOR
Device: NIV

Interventions

3 sonographic measurements after use of 30 minutes

Nasal high flow
NIVDEVICE

3 sonographic measurements after 30 minutes use

NIV

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • acute or chronic respiratory insufficiency with and/or hypercapnia,
  • age \> 18 years.
  • tolerate respiratory support devices
  • to sign a written declaration of consent

You may not qualify if:

  • Presence of respiratory insufficiency requiring intubation,
  • clinical instability,
  • metabolic acidosis or alkalosis,
  • Contraindication for NIV according to the S3 guideline,
  • serious concomitant illnesses,
  • unwillingness to co-operate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Leipzig

Leipzig, 04103, Germany

Location

MeSH Terms

Conditions

Respiratory Insufficiency

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This study is a randomised comparison of two investigational medical devices in a prospective, monocentric, randomised, physiological, open-label, cross-over study. Patients are randomised into two groups (study arms) with a randomisation ratio of 1:1.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical director, Head of department

Study Record Dates

First Submitted

January 3, 2025

First Posted

July 3, 2025

Study Start

July 1, 2019

Primary Completion

January 1, 2025

Study Completion

January 1, 2025

Last Updated

July 3, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will share

All data upon request

Shared Documents
STUDY PROTOCOL

Locations